Inhibikase Therapeutics (NASDAQ:IKT) Issues Earnings Results

by · The Cerbat Gem

Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.13) earnings per share (EPS) for the quarter, Zacks reports.

Inhibikase Therapeutics Price Performance

Shares of IKT stock traded down $0.07 on Friday, hitting $1.53. The stock had a trading volume of 76,766 shares, compared to its average volume of 109,381. The business has a 50 day simple moving average of $1.59. The stock has a market capitalization of $114.02 million, a price-to-earnings ratio of -1.68 and a beta of 0.89. Inhibikase Therapeutics has a 52-week low of $1.33 and a 52-week high of $4.20.

Analyst Ratings Changes

Several research analysts recently commented on IKT shares. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded Inhibikase Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Get Our Latest Stock Report on IKT

About Inhibikase Therapeutics

(Get Free Report)

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.

Featured Articles